Fineline Cube

Follow:
14417 Articles
Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH
CompanyDrug

Abbisko Therapeutics Presents Positive Phase II Results for Pimicotinib in cGvHD at ASH

Jacobio Pharma's BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study
CompanyDrug

Jacobio Pharma’s BET Inhibitor JAB-8263 Shows Promising Results in Myelofibrosis Phase I Study

Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026
CompanyDrug

Youcare Pharmaceutical Gets FDA Clearance for Herpes Zoster mRNA Vaccine YKYY026

Duality Biologics' DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial
CompanyDrug

Duality Biologics’ DB-1311 ADC Shows Promising Results in Global Phase 1/2a Trial

Chipscreen Biosciences' Chiauranib Phase III Trial Results for SCLC Announced
CompanyDrug

Chipscreen Biosciences’ Chiauranib Phase III Trial Results for SCLC Announced

Immunofoco's IMC002 CAR-T Therapy Receives FDA Fast Track Designation for Gastric Cancer
CompanyDrug

Immunofoco’s IMC002 CAR-T Therapy Receives FDA Fast Track Designation for Gastric Cancer

Shanghai Juncell Therapeutics has announced that the National Medical Products Administration's Center for Drug Evaluation (CDE) has approved the first pivotal Phase II registration clinical trial for its GC101 TIL injection. The trial, designated as NCT06703398, is for the treatment of advanced melanoma patients who have progressed or are intolerant to PD-1 antibody therapy. The study will be led by Professor Guo Jun, a global authority in melanoma treatment at Beijing Cancer Hospital, and will be conducted as a multicenter clinical research across China.
CompanyDrug

Shanghai Juncell Therapeutics’ GC101 TIL Therapy Receives CDE Approval for Pivotal Phase II Trial

AI Proteins Partners with Bristol Myers Squibb to Develop Miniprotein-Based Therapeutics
CompanyDeals

AI Proteins Partners with Bristol-Myers Squibb to Develop Miniprotein-Based Therapeutics

Novatim Immune Therapeutics' Y-0301 Receives FDA Clearance for Clinical Trials
CompanyDrug

Novatim Immune Therapeutics’ Y-0301 Receives FDA Clearance for Clinical Trials

NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation
Policy / Regulatory

NMPA Releases 85th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Hangzhou-Based HighField Biopharmaceutical Advances HF50 for HER-2 Tumors with NMPA Approval
CompanyDrug

HighField Biopharmaceutical’s HF50 Receives Tacit Clinical Approval from NMPA for HER-2 Positive Tumors

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment
CompanyDrug

Shenyang Hongqi Pharma Secures NMPA Approval for Pretomanid in TB Treatment